Adipose Tissue-Derived Stromal/Stem Cells Transplantation with Cholecalciferol Supplementation in Recent-Onset Type 1 Diabetes Patients: Twelve Months Follow-Up

Abstract

To evaluate safety and therapeutic effect along 12 months of allogenic adipose tissue-derived stromal/stem cells (ASCs) transplantation with cholecalciferol (VITD) in patients with recent-onset type 1 diabetes (T1D). Prospective, phase II, open trial, pilot study in which patients with recent onset T1D received ASCs (1xKgx10⁶ cells) and VITD 2000UI/day for 12 months (group 1) and were compared to controls with standard insulin therapy (group 2). Adverse events, C-peptide area under the curve (CPAUC), insulin dose, HbA1c and frequency of FoxP3+ in CD4+ or CD8+ T-cells(flow cytometry) were evaluated at baseline(T0), after 3(T3), 6(T6) and 12 months(T12). Eleven patients completed follow up (7:group 1;4:group 2). Group 1 had lower insulin requirement at T3(0.24±0.18vs0.53±0.23UI/kg,p=0.04), T6(0.24±0.15vs0.66±0.33 UI/kg,p=0.04) and T12(0.39±0.15vs0.74±0.29 UI/Kg,p=0.04).HbA1c was lower at T6 (50.57±8.56vs72.25±10.34 mmol/mol,p=0.01), without differences at T12 (57.14±11.98 in group 1 vs. 73.5±14.57 mmol/min in group 2, p=0.16). CPAUC was not significantly different between groups at T0(p=0.07), higher in group 1 at T3(p=0.04) and T6(p=0.006), but similar at T12(p=0.23). IDAA1c was significantly lower in group 1 than group 2 at T3,T6 and T12 (p=0.006, 0.006 and 0.042, respectively). IDDA1c was inversely correlated to FoxP3 expression in CD4 and CD8+ T cells at T6 (p<0.001 and p=0.01, respectively). In group 1, one patient had recurrence of a benign teratoma that was surgically removed, not associated to the intervention. ASCs with VITD without immunosuppression were safe and associated lower insulin requirements, better glycemic control, and transient better pancreatic function in recent onset T1D, but the potential benefits were not sustained.

Key words

diabetes mellitus type 1 - stem cells - vitamin D - insulin secretion

Publikationsverlauf

Eingereicht: 02. Januar 2023

Angenommen nach Revision: 15. Mai 2023

Accepted Manuscript online:
16. Mai 2023

Artikel online veröffentlicht:
29. Juni 2023

• References

• 1 Bluestone JA, Herold K, Eisenbarth G.. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010; 464: 1293-1300
• 2 Lachin JM, McGee P, Palmer JP. et al. Impact of C-peptide preservation on metabolic and clinical outcomes in the diabetes control and complications trial. Diabetes 2014; 63: 739-748
• 3 Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1998; 128: 517-523
• 4 Palmer JP, Fleming GA, Greenbaum CJ. et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004; 53: 250-264
• 5 Warshauer JT, Bluestone JA, Anderson MS.. New frontiers in the treatment of type 1 diabetes. Cell Metab 2020; 31: 46-61
• 6 Voltarelli JC, Couri CE, Stracieri AB. et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007; 297: 1568-1576
• 7 Couri CE, de Oliveira MC, Simões BP.. Risks, benefits, and therapeutic potential of hematopoietic stem cell transplantation for autoimmune diabetes. Curr Diab Rep 2012; 12: 604-611
• 8 Atkinson MA, Roep BO, Posgai A. et al. The challenge of modulating β-cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol 2019; 7: 52-64
• 9 Constantin G, Marconi S, Rossi B. et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 2009; 27: 2624-2635
• 10 Daumas A, Magalon J, Jouve E. et al. Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients. Curr Res Transl Med 2017; 65: 40-43
• 11 Garcia-Olmo D, Herreros D, Pascual M. et al. Treatment of enterocutaneous fistula in Crohn's Disease with adipose-derived stem cells: a comparison of protocols with and without cell expansion. Int J Colorectal Dis 2009; 24: 27-30
• 12 Gimble JM, Guilak F, Bunnell BA.. Clinical and preclinical translation of cell-based therapies using adipose tissue-derived cells. Stem Cell Res Ther 2010; 1: 19
• 13 Maria AT, Maumus M, Le Quellec A. et al. Adipose-derived mesenchymal stem cells in autoimmune disorders: state of the art and perspectives for systemic sclerosis. Clin Rev Allergy Immunol 2017; 52: 234-259
• 14 Figliuzzi M, Bonandrini B, Silvani S. et al. Mesenchymal stem cells help pancreatic islet transplantation to control type 1 diabetes. World J Stem Cells 2014; 6: 163-172
• 15 Abdi R, Fiorina P, Adra CN. et al. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 2008; 57: 1759-1767
• 16 Amer MG, Embaby AS, Karam RA. et al. Role of adipose tissue derived stem cells differentiated into insulin producing cells in the treatment of type I diabetes mellitus. Gene 2018; 654: 87-94
• 17 Dang LT, Bui AN, Le-Thanh Nguyen C. et al. Intravenous infusion of human adipose tissue-derived mesenchymal stem cells to treat type 1 diabetic mellitus in mice: an evaluation of grafted cell doses. Adv Exp Med Biol 2018; 1083: 145-156
• 18 Gan J, Wang Y, Zhou X.. Stem cell transplantation for the treatment of patients with type 1 diabetes mellitus: a meta-analysis. Exp Ther Med 2018; 16: 4479-4492
• 19 Riachy R, Vandewalle B, Kerr Conte J. et al. 1,25-Dihydroxyvitamin D 3 protects RINm5F and human islet cells against cytokine-induced apoptosis: implication of the antiapoptotic protein A20. Endocrinology 2002; 143: 4809-4819
• 20 Treiber G, Prietl B, Fröhlich-Reiterer E. et al. Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus — A randomized clinical trial. Clin Immunol 2015; 161: 217-224
• 21 Gabbay MA, Sato MN, Finazzo C. et al. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus. Arch Pediatr Adolesc Med 2012; 166: 601-617
• 22 Mishra A, Dayal D, Sachdeva N. et al. Effect of 6-months' vitamin D supplementation on residual beta cell function in children with type 1 diabetes: a case control interventional study. J Pediatr Endocrinol Metab 2016; 29: 395-400
• 23 Simpson M, Brady H, Yin X. et al. No association of vitamin D intake or 25-hydroxyvitamin D levels in childhood with risk of islet autoimmunity and type 1 diabetes: the diabetes autoimmunity study in the young (DAISY). Diabetologia 2011; 54: 2779-2788
• 24 Walter M, Kaupper T, Adler K. et al. No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care 2010; 33: 1443-1448
• 25 Gregoriou E, Mamais I, Tzanetakou I. et al. The effects of vitamin D supplementation in newly diagnosed type 1 diabetes patients: systematic review of randomized controlled trials. Rev Diabet Stud 2017; 14: 260-268
• 26 Araujo DB, Dantas JR, Silva KR. et al. Allogenic adipose tissue-derived stromal/stem cells and vitamin D supplementation in patients with recent-onset type 1 diabetes mellitus: a 3-month follow-up pilot study. Front Immunol 2020; 11: 993
• 27 Baptista LS, do Amaral RJFC, Carias RBV. et al. An alternative method for the isolation of mesenchymal stromal cells derived from lipoaspirate samples. Cytotherapy 2009; 11: 706-715
• 28 Professional Practice Committee. Standards of medical care in diabetes—2021. Diabetes Care 2021; 44: S3
• 29 Evert AB, Dennison M, Gardner CD. et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care 2019; 42: 731-754
• 30 Colberg SR, Sigal RJ, Yardley JE. et al. Physical activity/exercise and diabetes: a position statement of the American diabetes association. Diabetes Care 2016; 39: 2065-2079
• 31 Draznin B, Aroda VR, Bakris G. et al. Glycemic targets: standards of medical care in diabetes-2022. Diabetes Care 2022; 45: S83-S96
• 32 Nwosu BU.. Partial clinical remission of type 1 diabetes mellitus in children: clinical applications and challenges with its definitions. Eur Med J Diabetes 2019; 4: 89-98
• 33 Mortensen HB, Hougaard P, Swift P. et al. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 2009; 32: 1384-1390
• 34 Zhang Y, Chen W, Feng B. et al. The clinical efficacy and safety of stem cell therapy for diabetes mellitus: a systematic review and meta-analysis. Aging Dis 2020; 11: 141-153
• 35 Pittenger MF, Mackay AM, Beck SC. et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147
• 36 Jiang Y, Jahagirdar BN, Reinhardt RL. et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41-49
• 37 Ra JC, Shin IS, Kim SH. et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev 2011; 20: 1297-1308
• 38 Ra JC, Kang SK, Shin IS. et al. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med 2011; 9: 181
• 39 Multani J, Kives S.. Dermoid cysts in adolescents. Curr Opin Obstet Gynecol 2015; 27: 315-319
• 40 Fernández O, Izquierdo G, Fernández V. et al. Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. PLoS One 2018; 13: e0195891
• 41 Carlsson PO, Schwarcz E, Korsgren O. et al. Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes 2015; 64: 587-592
• 42 Hu J, Yu X, Wang Z. et al. Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J 2013; 60: 347-357
• 43 Petrou P, Kassis I, Levin N. et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain 2020; 143: 3574-3588
• 44 Von Scholten BJ, Kreiner FF, Gough SCL. et al. Current and future therapies for type 1 diabetes. Diabetologia 2021; 64: 1037-1048
• 45 Cernea S, Herold KC.. Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. Clin Immunol 2010; 134: 121-129
• 46 Long SA, Thorpe J, Herold KC. et al. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. Cell Immunol 2017; 319: 3-9
• 47 MacDonald A, Ambery P, Donaldson J. et al. Subcutaneous administration of otelixizumab is limited by injection site reactions: results of an exploratory study in type 1 diabetes mellitus patients. Exp Clin Endocrinol Diabetes 2016; 124: 288-293
• 48 Vudattu NK, Herold KC.. Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development. Expert Opin Biol Ther 2014; 14: 377-385
• 49 Puissant B, Barreau C, Bourin P. et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol 2005; 129: 118-129
• 50 Wsuji W, Rubin JP, Marra KG.. Adipose-derived stem cells: Implications in tissue regeneration. World J Stem Cells 2014; 6: 312-321
• 51 Rivera-Izquierdo M, Cabeza L, Láinez-Ramos-Bossini A. et al. An updated review of adipose derived-mesenchymal stem cells and their applications in musculoskeletal disorders. Expert Opin Biol Ther 2019; 19: 233-248
• 52 Couri CE, Oliveira MC, Stracieri AB. et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009; 301: 1573-1579
• 53 Couri CEB, Malmegrim KCR, Oliveira MC.. New horizons in the treatment of type 1 diabetes: more intense immunosuppression and beta cell replacement. Front Immunol 2018; 9: 1086
• 54 Niedzwiecki P, Pilacinski S, Uruska A. et al. Influence of remission and its duration on development of early microvascular complications in young adults with type 1 diabetes. J Diabetes Complicat 2015; 29: 1105-1111
• 55 Christoffersson G, von Herrath M.. Regulatory immune mechanisms beyond regulatory T cells. Trends Immunol 2019; 40: 482-491
• 56 Bisikirska B, Colgan J, Luban J. et al. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 2005; 115: 2904-2913
• 57 Bluestone JA, Buckner JH, Fitch M. et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med 2015; 7: 315ra189
• 58 Haller MJ, Wasserfall CH, McGrail KM. et al. Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. Diabetes Care 2009; 32: 2041-2046
• 59 Aronson R, Gottlieb PA, Christiansen JS. et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 2014; 37: 2746-2754
• 60 Hagopian W, Ferry RJ, Sherry N. et al. Protégé Trial Investigators. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes 2013; 62: 3901-3908
• 61 Dantas JR, Araújo DB, Silva KR. et al. Adipose tissue-derived stromal/stem cells+cholecalciferol: a pilot study in recent-onset type 1 diabetes patients. Arch Endocrinol Metab 2021; 65: 342-351
• 62 Nwosu BU, Parajuli S, Jasmin G. et al. Ergocalciferol in new-onset type 1 diabetes: a randomized controlled trial. J Endocr Soc 2022; 6: 1-13
• 63 Chavakis E, Urbich C, Dimmeler S.. Homing and engraftment of progenitor cells: a prerequisite for cell therapy. J Mol Cell Cardiol 2008; 45: 514-522
• 64 Deak E, Seifried E, Henschler R.. Homing pathways of mesenchymal stromal cells (MSCs) and their role in clinical applications. Int Rev Immunol 2010; 29: 514-529
• 65 Ra JC, Kang SK, Shin IS. et al. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med 2011; 9: 181
• 66 De Becker A, Riet IV.. Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy?. World J Stem Cells 2016; 8: 73-87